Can GLP-1 agonists like Ozempic, Wegovy, and Mounjaro be used to treat addiction?

The GLP-1 and Addiction Connection: Anna Lembke's Perspective

Dr. Anna Lembke, a Stanford addiction medicine specialist and the author of Dopamine Nation, sits down to discuss what might be the most unexpected development in GLP-1 research: the possibility that these weight-loss drugs could help treat addiction. This is not fringe speculation. Multiple lines of evidence, from animal studies to patient anecdotes to early clinical investigations, suggest that GLP-1 receptor agonists may reduce the desire to consume more than food, but also alcohol, nicotine, opioids, and other addictive substances. If this pans out, it could represent a model shift in addiction treatment.

Lembke starts by explaining the biological basis for why GLP-1 agonists might affect addiction. The GLP-1 receptor is more than present in the gut and pancreas. It is also found in the brain's reward circuitry, particularly in the nucleus accumbens and the ventral tegmental area, which are the same regions that mediate the rewarding effects of drugs, alcohol, and addictive behaviors. When you take a GLP-1 agonist, it is more than reducing your appetite for food. It appears to be modulating the reward system more broadly, turning down the volume on the signals that make addictive substances feel compelling.

This is consistent with what many GLP-1 users have reported anecdotally: reduced interest in alcohol, less desire to smoke, diminished cravings for shopping or gambling, and a general sense that the compulsive pull toward rewarding behaviors has quieted. Lembke is careful to note that anecdotes are not data, but she acknowledges that the sheer volume of these reports, combined with the neurobiological plausibility, makes a strong case for rigorous investigation.

The Animal Research and Early Human Data

The video covers the preclinical evidence in some detail. Animal studies have shown that GLP-1 agonists reduce alcohol intake in rats bred to prefer alcohol. They reduce cocaine-seeking behavior. They reduce nicotine self-administration. In each case, the mechanism appears to involve modulation of dopamine signaling in the reward circuit. The GLP-1 agonist does not block the reward entirely (the way naltrexone blocks opioid receptors), but it seems to reduce the magnitude of the reward, making the substance less compelling without making it aversive.

The human data is earlier and more limited but heading in the same direction. Several observational studies have found that patients prescribed GLP-1 agonists for diabetes or obesity have lower rates of alcohol use disorder diagnoses compared to matched controls. These are correlational findings that cannot prove causation, but they are consistent with the animal data and the anecdotal reports. Randomized controlled trials specifically studying GLP-1 agonists for addiction are now underway, and Lembke expresses cautious optimism about what they might show.

She also discusses the distinction between wanting and liking, which is central to understanding addiction neuroscience. Addiction is often characterized by excessive wanting (craving, compulsion) even when the liking (pleasure from the substance) has diminished. GLP-1 agonists appear to reduce the wanting component specifically, which aligns with their effects on the mesolimbic dopamine system. If this is confirmed, it would make them mechanistically distinct from most current addiction treatments and potentially useful for a broad range of addictive behaviors rather than just substance-specific addictions.

The Caution: What We Do Not Know Yet

Lembke is a rigorous scientist, and she spends significant time on the limitations and unknowns. We do not yet know what dose of GLP-1 agonist would be effective for addiction treatment. The doses used for weight loss may be different from what is needed for reward modulation. We do not know whether the anti-addiction effects persist long-term or whether tolerance develops. We do not know how GLP-1 agonists would interact with other addiction medications like naltrexone or buprenorphine. And we do not know whether the weight loss itself (rather than the direct brain effects) is contributing to reduced substance use, since improving metabolic health can affect mood and behavior independently.

She is particularly thoughtful about the risk of overpromising. The addiction treatment field has a history of announcing "breakthroughs" that do not pan out in rigorous trials. GLP-1 agonists might reduce addictive behaviors, or they might only help a subset of patients, or the effect might be too small to be clinically meaningful. The right response is to fund the trials, run them well, and let the data guide clinical practice rather than rushing to prescribe GLP-1s off-label for addiction based on preliminary evidence and patient anecdotes.

Lembke also raises an ethical consideration: if GLP-1 agonists do reduce the desire for rewarding experiences broadly, what are the implications for quality of life? Addiction involves pathological levels of reward-seeking, but reward-seeking itself is a normal and healthy part of human experience. A drug that broadly dampens reward signaling might reduce addictive cravings but also reduce the enjoyment of music, social connection, creative work, and other positive experiences. This is a question that the ongoing trials should address through quality-of-life measurements.

What This Discussion Gets Right and Where It Leaves Gaps

Lembke brings exactly the right combination of expertise and intellectual honesty to this topic. Her background in addiction medicine gives her the clinical context to evaluate the evidence rigorously. Her willingness to acknowledge both the promise and the uncertainty is refreshing in a media environment that tends toward either breathless enthusiasm or dismissive skepticism. The neurobiological explanations are accurate and accessible, and the ethical considerations she raises elevate the discussion beyond simple drug-effectiveness questions.

The gap is on the practical side. Viewers who are struggling with addiction and want to know "should I ask my doctor about a GLP-1?" do not get a clear answer, which is appropriate given the evidence but may be frustrating. The video could benefit from a more explicit discussion of the existing evidence-based addiction treatments that are available now, so that viewers are not left in a holding pattern waiting for GLP-1 addiction trials to conclude.

The distinction between reward pathway modulation and reward pathway suppression is clinically important and Lembke explains it well. Existing addiction medications tend to work by either blocking the reward entirely (naltrexone blocks opioid receptors so that opioids produce no euphoria) or by substituting a controlled reward (methadone and buprenorphine provide a milder opioid effect that reduces cravings for stronger opioids). GLP-1 agonists appear to work through a different mechanism: they do not block reward and they do not substitute for the addictive substance. Instead, they seem to reduce the motivational salience of rewards, making addictive substances less compelling without making them aversive. This is a subtler and potentially more broadly applicable approach because it does not require receptor-specific targeting. It modulates the general reward circuitry that underlies many different types of addiction.

The epidemiological data connecting GLP-1 use to reduced alcohol and substance use disorders is growing and worth following closely. Large database studies using electronic health records have found that patients prescribed GLP-1 agonists for diabetes have 30-50% lower rates of alcohol use disorder diagnosis compared to patients prescribed other diabetes medications. Similar patterns have been observed for opioid use disorder and smoking. These are observational findings that cannot prove causation (there may be confounding factors that explain the association), but the consistency of the signal across multiple databases, multiple countries, and multiple substance types strengthens the case that something real is going on rather than a statistical artifact.

The potential implications for public policy are enormous if the addiction findings hold up in randomized trials. Alcohol use disorder affects approximately 29 million Americans. Opioid use disorder has been declared a national emergency. Nicotine addiction kills more than 480,000 Americans annually. If GLP-1 agonists even modestly reduce the prevalence or severity of these conditions, the public health impact would be measured in thousands of lives saved and billions of dollars in reduced healthcare and social costs. This is one of the reasons the ongoing clinical trials are attracting attention more than from the medical community but from public health agencies, insurance companies, and policymakers who are looking for new tools to address addiction at scale.

Questions to Explore With Your Provider

If you are dealing with addiction and are curious about the GLP-1 connection, here are productive questions. Are there clinical trials studying GLP-1 agonists for my specific type of addiction that I could participate in? If I am already on a GLP-1 for weight management and have noticed reduced cravings for substances, should we adjust our addiction treatment plan accordingly? What evidence-based addiction treatments are available to me right now while the GLP-1 research develops? If I am on addiction medication (naltrexone, buprenorphine, etc.), are there any known interactions with GLP-1 agonists?

Who Should Watch This

This video is essential for anyone in the addiction space, whether as a patient, a provider, or a researcher. Lembke's analysis is the most scientifically grounded discussion of the GLP-1/addiction connection currently available in video format. It is also valuable for GLP-1 users who have noticed changes in their relationship with alcohol, nicotine, or other substances and want to understand why. Prescribers who treat patients with co-occurring obesity and substance use disorders will find the mechanistic discussion directly relevant to their clinical thinking. And anyone interested in neuroscience and reward pathways will find the brain science fascinating regardless of whether addiction is personally relevant.